• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CytomX Therapeutics upgraded by Piper Sandler with a new price target

    5/28/24 7:31:35 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTMX alert in real time by email
    Piper Sandler upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $3.50 from $2.25 previously
    Get the next $CTMX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTMX

    DatePrice TargetRatingAnalyst
    5/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    4/14/2025$3.25 → $2.50Overweight
    Piper Sandler
    5/28/2024$2.25 → $3.50Neutral → Overweight
    Piper Sandler
    5/9/2024$8.00Neutral → Outperform
    Wedbush
    5/6/2024$2.50 → $8.00Hold → Buy
    Jefferies
    4/22/2024Underweight → Neutral
    JP Morgan
    11/14/2022$3.00 → $2.60Outperform → Market Perform
    BMO Capital Markets
    7/7/2022$16.00 → $4.00Buy → Neutral
    Mizuho
    More analyst ratings

    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Ogden Christopher sold $33,381 worth of shares (12,255 units at $2.72) and converted options into 37,500 shares, increasing direct ownership by 13% to 226,271 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      6/17/25 4:11:18 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Scientific Officer Belvin Marcia converted options into 37,500 shares and sold $37,334 worth of shares (13,884 units at $2.69), increasing direct ownership by 9% to 272,252 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      6/17/25 4:10:00 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Mccarthy Sean A. converted options into 150,000 shares and sold $149,264 worth of shares (55,511 units at $2.69), increasing direct ownership by 9% to 1,089,684 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      6/17/25 4:09:02 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care